298 related articles for article (PubMed ID: 17237002)
1. [Immunotherapy and malignant mesothelioma: clinical perspectives].
Grégoire M; Ebstein F
Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
[TBL] [Abstract][Full Text] [Related]
2. What's the place of immunotherapy in malignant mesothelioma treatments?
Grégoire M
Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy-based treatment strategies for malignant mesothelioma.
Schwarzenberger P; Byrne P; Kolls JK
Curr Opin Mol Ther; 1999 Feb; 1(1):104-11. PubMed ID: 11249674
[TBL] [Abstract][Full Text] [Related]
4. [Current insights in malignant pleural mesothelioma].
Bard M; Debrosse D; Caliandro R; Girard P; Grunenwald D; Ruffié P
Bull Cancer; 2002 Jan; 89(1):67-74. PubMed ID: 11847028
[TBL] [Abstract][Full Text] [Related]
5. Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?
Lucchi M; Picchi A; Alí G; Chella A; Guglielmi G; Cristaudo A; Fontanini G; Mussi A
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):572-6. PubMed ID: 20053697
[TBL] [Abstract][Full Text] [Related]
6. Mesothelioma: path to multimodality treatment.
Su S
Semin Thorac Cardiovasc Surg; 2009; 21(2):125-31. PubMed ID: 19822284
[TBL] [Abstract][Full Text] [Related]
7. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
[TBL] [Abstract][Full Text] [Related]
8. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
9. Multidisciplinary treatment of malignant pleural mesothelioma.
Ceresoli GL; Gridelli C; Santoro A
Oncologist; 2007 Jul; 12(7):850-63. PubMed ID: 17673616
[TBL] [Abstract][Full Text] [Related]
10. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting.
Ampollini L; Soltermann A; Felley-Bosco E; Lardinois D; Arni S; Speck RF; Weder W; Opitz I
Eur J Cardiothorac Surg; 2009 Mar; 35(3):457-62. PubMed ID: 19162494
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
Lucchi M; Chella A; Melfi F; Dini P; Ambrogi M; Fino L; Fontanini G; Mussi A
Eur J Cardiothorac Surg; 2007 Mar; 31(3):529-33; discussion 533-4. PubMed ID: 17188885
[TBL] [Abstract][Full Text] [Related]
12. Malignant mesothelioma 2008.
Zervos MD; Bizekis C; Pass HI
Curr Opin Pulm Med; 2008 Jul; 14(4):303-9. PubMed ID: 18520263
[TBL] [Abstract][Full Text] [Related]
13. [Malignant pleural mesothelioma in 1997].
Viallat JR; Boutin C; Kasseyet S
Schweiz Med Wochenschr; 1997 Oct; 127(41):1707-11. PubMed ID: 9441378
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.
Tsao AS; Mehran R; Roth JA
Clin Lung Cancer; 2009 Jan; 10(1):36-41. PubMed ID: 19289370
[TBL] [Abstract][Full Text] [Related]
15. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
[TBL] [Abstract][Full Text] [Related]
16. [Environmental cancer: malignant pleural mesothelioma].
Margery J; Ruffié P
Bull Cancer; 2008 Jan; 95(1):77-86. PubMed ID: 18230573
[TBL] [Abstract][Full Text] [Related]
17. Future developments in the management of malignant pleural mesothelioma.
Zucali PA; De Vincenzo F; Simonelli M; Santoro A
Expert Rev Anticancer Ther; 2009 Apr; 9(4):453-67. PubMed ID: 19374599
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma.
Sterman DH; Molnar-Kimber K; Iyengar T; Chang M; Lanuti M; Amin KM; Pierce BK; Kang E; Treat J; Recio A; Litzky L; Wilson JM; Kaiser LR; Albelda SM
Cancer Gene Ther; 2000 Dec; 7(12):1511-8. PubMed ID: 11228529
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
Wong RM; Ianculescu I; Sharma S; Gage DL; Olevsky OM; Kotova S; Kostic MN; Grundfest WS; Hou D; Cameron RB
Am J Respir Cell Mol Biol; 2014 May; 50(5):870-5. PubMed ID: 24450537
[TBL] [Abstract][Full Text] [Related]
20. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
Watanabe Y; Kojima T; Kagawa S; Uno F; Hashimoto Y; Kyo S; Mizuguchi H; Tanaka N; Kawamura H; Ichimaru D; Urata Y; Fujiwara T
Oncogene; 2010 Feb; 29(8):1145-54. PubMed ID: 19935710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
